Fulcrum Therapeutics, Inc. (FULC)

Over the past six months, Fulcrum Therapeutics' stock price has been influenced by positive Phase 1b trial results for pociredir, public offerings, Q3 and Q4 2025 earnings reports, analyst ratings and price fluctuations, and a partnership announcement. Positive trial results led to increased share prices, while public offerings involved the announcement and pricing of common stock offerings. Earnings reports showed mixed results, with Q3 GAAP EPS missing estimates but Q4 GAAP EPS aligning with estimates. Analyst ratings varied, with some setting target prices and restating outperform ratings, while others downgraded the stock. Fulcrum partnered with MedicAlert Foundation and the Sickle Cell Disease Association of America, Inc. to improve emergency department access to critical care information for people with sickle cell disease.

Information regarding demand seasonality for Fulcrum Therapeutics, Inc.'s products and services is not publicly available in the provided search results. As a clinical-stage biopharmaceutical company, its revenue generation is primarily tied to collaboration agreements and the progression of its pipeline, rather than direct product sales to consumers which might exhibit seasonal patterns.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecules for genetically defined rare diseases with high unmet medical needs. The company operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry, with a focus on Drug Discovery and Biotechnology. Its lead clinical program is pociredir, an oral small molecule designed to induce fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia. Another product candidate, losmapimod, was in a Phase 3 clinical trial for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum also has discovery programs targeting Diamond-Blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, and fibrotic disorders, with plans to submit an IND application for Diamond-Blackfan anemia during the fourth quarter of 2025.

Fulcrum Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States.

Fulcrum Therapeutics maintains a brand reputation focused on scientific leadership and a patient-centered culture, aiming to develop therapies that transform the lives of patients and caregivers in the rare disease community. Positive clinical trial results for pociredir and a strategic partnership with MedicAlert Foundation and the Sickle Cell Disease Association of America, Inc. have positively contributed to its reputation.

Fulcrum Therapeutics, Inc. has significant institutional ownership, with 168 institutional owners and shareholders holding a total of 62,181,508 shares as of April 8, 2026, representing approximately 101.27% of the company. Insiders own about 43.39%. Major institutional owners include Suvretta Capital Management, Llc, Ra Capital Management, L.p., and Nantahala Capital Management, LLC, among others. The largest individual shareholder is Ra Capital Management LP, owning 13.05 million shares, representing 19.60% of the company. Mark J. Levin is also a significant insider owner.